Description
GPC3 refers to glypican-3-targeted cellular immunotherapy, specifically engineered tumor-infiltrating lymphocytes (TILs) or chimeric antigen receptor T-cells (CAR-T cells) designed to recognize and attack cancer cells expressing the GPC3 protein. This cellular immunotherapy approach involves extracting immune cells from patients, genetically modifying them to target GPC3-positive cancer cells, and reinfusing them to treat advanced solid tumors including colorectal cancer. GPC3-targeted therapies represent a personalized cellular immunotherapy strategy for patients with GPC3-expressing malignancies.
Mechanism of Action
The engineered immune cells are modified to express receptors that specifically recognize glypican-3 (GPC3), a cell surface proteoglycan that is overexpressed in various solid tumors including some colorectal cancers. Once infused, these modified T-cells bind to GPC3 on tumor cell surfaces, leading to targeted cancer cell destruction through cytotoxic T-cell responses and immune system activation.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
| Administration | IV |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.